Group 1: Financial Performance - In the first three quarters of 2025, the company achieved a total revenue of 7.9 billion CNY, a year-on-year increase of 30.1% [1] - The medical segment generated 3.83 billion CNY, growing by 44.4%, while the consumer segment reached 4.01 billion CNY, with a growth of 19.1% [1] - The overall gross margin improved due to a higher proportion of high-value, high-margin products in the medical segment [1][8] Group 2: Sales Channels and Growth - Overseas sales in the medical segment accounted for 57% of revenue, with a year-on-year growth of 81.7% [2] - E-commerce channels in the consumer segment grew by 23.5%, with Douyin (TikTok) and interest e-commerce showing nearly 80% growth [2] - The supermarket channel saw a 53.4% increase, indicating rapid development in core channels [2] Group 3: Product Performance - The sanitary napkin category saw a 56% year-on-year revenue increase, driven by new product launches [3] - The adult clothing segment experienced a 13% growth, focusing on comfortable home and innerwear [3] - High-end dressing products in the medical segment achieved significant growth, with surgical consumables and high-end dressings showing increases of 185.3% and 26.2%, respectively [16] Group 4: Strategic Outlook - The company plans to enhance its product offerings in adult clothing and sanitary napkins, focusing on consumer needs and market trends [4] - Future strategies include expanding overseas markets, particularly in Southeast Asia and the Middle East, with a focus on high-end dressing products [5][14] - The company has completed a three-year strategic plan for both medical and consumer segments, emphasizing product and channel development [18] Group 5: Integration and Management - The integration of GRI is progressing positively, with improved supply chain performance and enhanced client confidence [6] - The management has implemented a global functional management model to improve operational efficiency [6] - The company is committed to sustainable growth and delivering verifiable performance to investors [18]
稳健医疗(300888) - 2025年10月28日投资者关系活动记录表